4 days Ago By ABMN Staff
Virpax Pharmaceuticals, Inc. ( NASDAQ:VRPX – Get Free Report ) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 319,800 shares, a growth of 1,284.
4% from the March 15th total of 23,100 shares. Based on an average daily trading volume, of 386,500 shares, the short-interest ratio is currently 0.8 days.
Currently, 26.2% of the company’s stock are short sold. Hedge Funds Weigh In On Virpax Pharmaceuticals An institutional investor recently bought a new position in Virpax Pharmaceuticals stock.
Garden State Investment Advisory Services LLC purchased a new stake in shares of Virpax Pharmaceuticals, Inc. ( NASDAQ:VRPX – Free Report ) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 57,300 shares of the company’s stock, valued at approximately $40,000.
Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 32.
23% of the company’s stock. Virpax Pharmaceuticals Trading Down 11.5 % VRPX stock opened at $0.
23 on Wednesday. The company has a 50 day moving average of $3.72 and a two-hundred day moving average of $9.
00. Virpax Pharmaceuticals has a 12-month low of $0.13 and a 12-month high of $101.
00. About Virpax Pharmaceuticals Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.
Featured Articles Receive News & Ratings for Virpax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virpax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
